Expression Of ERO1L And DSG2 In Non-small Cell Lung Cancer And The Relationship With Clinical Prognosis

Objective: By detecting the expression levels of ERO1 L and DSG2 in NSCLC tissues and paracancer tissue,the differences in their expression in different pathological types and stages were analyzed,and then the relationship between ERO1 L and DSG2 and their correlation with the long-term prognosis of lung cancer patients were discussed,providing guidance for the prognosis evaluation of NSCLC.Methods: From January 2017 to December 2017,82paraffin-embedded cancer tissue samples(32 cases of lung squamous cell carcinoma,50 cases of lung adenocarcinoma)and 13 cases of paracancer tissue paraffin-embedded samples were selected from the thoracic surgery Department and Thoracic Cardiovascular Surgery Department of the First Affiliated Hospital of Hebei North University who underwent lung cancer resection and were confirmed as non-small cell lung cancer by the pathology department after surgery.Useing immunohistochemical staining(IHC)to detect the expression levels of ERO1 L and DSG2 proteins in cancer tissues and adjacent tissues,and the percentage of positive stained cells after staining was multiplied by the corresponding staining intensity to obtain the final expression score.Clinical data collection and follow-up of patients were completed.Count data were expressed as frequency(n)or percentage(%).Useing chi-square test,continuity correction Chi-square test or Fisher exact probability method to accomplish the two groups comparison;Measurement data conforming to normal distribution were expressed as mean ± standard deviation((?)±s),and independent sample t test was used for comparison between the two groups.Spearman rank correlation method was used to analyze the correlation between ERO1 L and DSG2 expression levels.Log-Rank test was used to evaluate the correlation between ERO1 L and DSG2 expression and prognosis of NSCLC patients,and Kaplan-Meier survival curve was plotted.Results: 1.There were no significant differences in gender,age and smoking history between the cancer tissue group and the adjacent tissue group(P>0.05).2.The expression levels of ERO1 L and DSG2 in NSCLC cancer tissues were significantly higher than in paracancer tissues,and the difference were statistically significant(P<0.001).3.General data(including gender,age and smoking history)at different expression levels of ERO1 L and DSG2 in NSCLC cancer tissues were compared,and there was no statistical significance(P>0.05).4.The expression differences of ERO1 L and DSG2 under different clinicopathological characteristics in NSCLC cancer tissues were compared,and the results showed that: The expression of ERO1 L was related to lymph node metastasis,tumor differentiation degree and tumor size.In cancer tissues with lymph node metastasis(P<0.05),moderate and low differentiation(P<0.01),and tumor >3cm(P<0.05),ERO1 L level increased more significantly.There was no significant difference in the expression of ERO1 L in different pathological type and TNM-staging(P>0.05).The expression of DSG2 was related to TNM stage,tumor differentiation degree and lymph node metastasis.The expression level of DSG2 in cancer tissues with early TNM tumor stage(I-II)was lower than that in cancer tissues with advanced TNM stage(III)(P<0.01).For moderately poorly differentiated tumors,a significant increase in DSG2 expression was observed(P<0.01).In cancer tissues with lymph node metastasis,DSG2 expression level was higher than that in cancer tissues without lymph node metastasis(P<0.05).There was no significant correlation between DSG2 expression and other clinicopathologic features(including pathological type and tumor size)(P>0.05).5.Spearman rank correlation showed that ERO1 L was positively correlated with DSG2 expression in non-small cell lung cancer(rs=0.5283,P<0.001);6.Kaplan-Meier survival analysis showed that the mean survival time of patients with low ERO1 L expression and high ERO1 L expression were 49.1(95%CI: 43.725～54.441)and 39.9 months(95%CI:34.587～45.217),the mean survival time of patients with low DSG2 expression and high DSG2 expression were 48.1(95%CI: 42.499～53.787)and 40.8 months(95%CI: 35.572～46.024).Log-Rank test showed that the 60-month cumulative survival rate of patients with low ERO1 L and DSG2 expression was higher than that of patients with ERO1 L and DSG2 high expression,and the difference was statistically significant(P<0.05).Further pair-based comparison showed that high expression of both ERO1 L and DSG2 significantly reduced the overall survival time of patients,and patients in DSG2+ERO1L+ group had shorter overall survival time than those in DSG2-ERO1L-group(P < 0.01).Conclusion: 1.The expression levels of ERO1 L and DSG2 in NSCLC cancer tissues were up-regulated.ERO1 L expression was related to tumor size,lymph node metastasis and tumor differentiation,but not with pathological type and TNM stage.DSG2 expression was correlated with lymph node metastasis,TNM stage and tumor differentiation,but not with pathological type and tumor size.2.The expression of ERO1 L in NSCLC tissues is positively correlated with the expression of DSG2,which jointly regulates the occurrence,development,invasion and metastasis of NSCLC.3.High expression of ERO1 L or DSG2 is associated with shorter overall survival of patients,and high expression of ERO1 L and DSG2 together significantly reduces overall survival of patients.